

	2019	2020	2021	Δ 2021-2019	GRI Indicator
<b>Climate Change - Public Targets</b>					
Scope 1 + 2 (metric ton (mt) CO <sub>2</sub> e)	1,282,023	1,186,483	1,181,996	↓ 8%	305-3
Renewable Energy (%)	9.6	5.1	8.7	↓ 9%	-
Scope 3 – Business travel carbon emissions (mt CO <sub>2</sub> e)	351,623	96,315	29,339	↓ 92%	305-3
Scope 3 – Upstream transportation & distribution carbon emissions (mt CO <sub>2</sub> e)	509,041	517,588	685,184	↑ 35%	305-3
Scope 3 – Suppliers of purchased goods and services by spend with science-based targets (%)	-	-	10	-	305-3

Pfizer is committed to achieving Net-Zero greenhouse gas (GHG) emissions by 2040. Our near-term climate goals, approved by the Science Based Targets initiative, are to:

- Reduce Scope 1+2 GHG emissions **46%** by 2030 from a 2019 baseline
- Source **80%** of electricity from renewables by 2025 and **100%** by 2030
- Reduce GHG emissions from business travel **25%** by 2025 from a 2019 baseline
- Reduce GHG emissions from upstream transportation and distribution **10%** by 2025 from a 2019 baseline
- Catalyze **64%** of our suppliers of goods and services by spend to set science-based targets by 2025

	2019	2020	2021	Δ 2021-2020	Δ 2021-2019	GRI Indicator
<b>Climate Change – Additional Metrics</b>						
Scope 1 (mt CO <sub>2</sub> e)	704,815	651,198	662,438	↑ 2%	↓ 6%	305-1
Scope 2, market-based (mt CO <sub>2</sub> e)	577,268	535,285	519,558	↓ 3%	↓ 10%	305-2
Scope 2, location-based (mt CO <sub>2</sub> e)	567,645	515,329	502,139	↓ 3%	↓ 12%	305-2
Scope 1 + 2 Emissions Intensity (mt CO <sub>2</sub> e/million USD Sales)	15.73	14.54	14.28	↓ 2%	↓ 9%	305-4
Energy Consumed (MWh)	4,362,417	4,274,003	4,326,443	↑ 1%	↓ 1%	302-1
Energy Intensity (MWh/ million USD Sales)	53.67	52.58	53.22	↑ 1%	↓ 1%	302-3
Scope 3 – Purchased goods and services (mt CO <sub>2</sub> e)	3,794,093	2,526,537	3,374,782	↑ 33%	↓ 11%	305-3
Scope 3 – Capital goods (mt CO <sub>2</sub> e)	345,953	191,894	251,040	↑ 31%	↓ 27%	305-3
Scope 3 – Fuel-and-energy-related activities not in Scope 1 or 2 (mt CO <sub>2</sub> e)	252,909	203,093	269,938	↑ 33%	↑ 7%	305-3
Scope 3 – Waste generated in operations (mt CO <sub>2</sub> e)	16,420	14,940	9,164	↓ 39%	↓ 44%	305-3
Scope 3 – Employee commuting (mt CO <sub>2</sub> e)	60,645	48,414	56,832	↑ 17%	↓ 6%	305-3
Scope 3 – Upstream leased assets (mt CO <sub>2</sub> e)	36,273	30,522	29,452	↓ 4%	↓ 19%	305-3
Scope 3 – Downstream transportation and distribution (mt CO <sub>2</sub> e)	99,576	7,295	12,969	↑ 78%	↓ 87%	305-3
Scope 3 – Investments (mt CO <sub>2</sub> e)	33,892	36,839	36,178	↓ 2%	↑ 7%	305-3
Scope 3 – Total (mt CO <sub>2</sub> e)	5,500,426	3,673,438	4,754,879	↑ 29%	↓ 14%	305-3



	2019	2020	2021	Δ 2021-2020	Δ 2021-2019	GRI Indicator
<b>Water</b>						
Water withdrawal excluding non-contact cooling water (million m <sup>3</sup> )	13.6	13.0	12.7	↓ 2%	↓ 6%	303-3
Water withdrawal including non-contact cooling water (million m <sup>3</sup> )	34.8	32.4	27.5	↓ 15%	↓ 21%	303-3
Third-party water (million m <sup>3</sup> )	8.7	8.3	8.0	↓ 3%	↓ 8%	303-3
Surface water withdrawal (million m <sup>3</sup> )	0.83	0.80	0.87	↑ 8%	↑ 5%	303-3
Groundwater withdrawal (million m <sup>3</sup> )	25.3	23.4	18.6	↓ 20%	↓ 26%	303-3
Brackish/seawater withdrawal (million m <sup>3</sup> )	0	0	0	-	-	303-3
Water discharged (million m <sup>3</sup> )	31.8	29.5	24.5	↓ 17%	↓ 23%	303-4
Water consumed (million m <sup>3</sup> )	3.1	3.0	3.1	↑ 2%	0%	303-4
<b>Waste</b>						
Hazardous waste generated (million kg)	120.2	114.0	82.7	↓ 28%	↓ 31%	306-3
Hazardous waste diverted from disposal (million kg)	43.1	42.5	19.5	↓ 54%	↓ 55%	306-4
Hazardous waste incinerated with energy recovery (million kg)	39.8	43.6	41.5	↑ 4%	↓ 5%	306-5
Hazardous waste incinerated without energy recovery (million kg)	22.2	23.1	17.8	↓ 23%	↓ 20%	306-5
Hazardous waste landfilled (million kg)	0.2	0.1	0.1	↓ 23%	↓ 66%	306-5
Hazardous waste other treatment (million kg)	7.4	4.7	3.8	↓ 19%	↓ 49%	306-5
Hazardous waste diverted from disposal (%)	36	37	24	-	-	306-4
Non-hazardous waste generated	37.9	36.9	40.1	↑ 9%	↑ 6%	306-3
Non-hazardous waste diverted from disposal (million kg)	16.6	17.4	24.0	↑ 38%	↑ 44%	306-4
Non-hazardous waste incinerated with energy recovery (million kg)	4.4	4.4	4.7	↑ 6%	↑ 8%	306-5
Non-hazardous waste incinerated without energy recovery (million kg)	0.9	1.3	0.6	↓ 49%	↓ 42%	306-5
Non-hazardous waste landfilled (million kg)	15.2	13.7	10.6	↓ 23%	↓ 31%	306-5
Non-hazardous waste other treatment (million kg)	0.1	0.2	0.2	↑ 33%	↑ 82%	306-5
Non-hazardous waste diverted from disposal (%)	44	47	60	-	-	306-4
<b>Air Emissions</b>						
Ozone depleting substances (mt CFC-11 equivalent)	618	4,363	447	↓ 90%	↓ 28%	305-6
Volatile organics (thousand kg)	371.6	379.6	295.8	↓ 22%	↓ 20%	305-7

	2019	2020	2021	Δ 2021-2020	Δ 2021-2019	GRI Indicator
<b>Health &amp; Safety</b>						
Fatalities	2	0	0	-	-	403-9 403-10
Recordable injuries & illnesses	392	260	248	↓ 5%	↓ 37%	403-9 403-10
Lost time injuries & illnesses	161	121	115	↓ 5%	↓ 29%	403-9 403-10
Hours worked (millions)	198.70	189.60	165.35	↓ 13%	↓ 17%	403-9 403-10
Total Injury & Illness Rate (Recordable cases per 200,000 hours worked)	0.39	0.27	0.30	↑ 11%	↓ 23%	403-9 403-10
Total Lost Time Injury & Illness Rate (Lost time cases per 200,000 hours worked)	0.16	0.13	0.14	↑ 8%	↓ 13%	403-9 403-10
Fleet Safety (Collisions per million km driven)	7.31	6.29	7.60	↑ 21%	↑ 4%	-
<b>Compliance</b>						
Penalties paid (currency equivalent USD)	12,500	4,400	50	↓ 99%	↓ 100%	307-1
Supplier EHS assessments (number performed)	102	46	122	↑ 165%	↑ 20%	308-2

## NOTES

↓=decrease (reduction) ↑=increase

Pfizer's organizational boundaries for environmental performance include all owned sites and leased facilities where Pfizer has operational control. Environmental data are baseline adjusted to reflect acquisitions and divestitures, reported absolute, using boundaries per the World Resources Institute (WRI) Greenhouse Gas (GHG) Protocol.

### Climate Change

#### Scope 1 & 2

- 2019 data has been adjusted to reflect divestitures and emission factor updates and is independently verified to the limited assurance level; 2021 data is independently verified to the reasonable assurance level.
- Scope 1 emissions include CO<sub>2</sub>, CH<sub>4</sub>, N<sub>2</sub>O, SF<sub>6</sub>, and HFCs using IPCC Fifth Assessment Report (AR5-100 year) Global Warming Potential (GWP) rates; volatile organic emissions are calculated using an emission factor representative of solvents typically used by Pfizer sites.
- Scope 2 emissions are reported in accordance with GHG Protocol Scope 2 Guidance as location- and market-based emissions. Location-based emissions are calculated based on the average emissions intensity of the grid for the region where energy is consumed. Market-based emissions are calculated based on the electricity procured by individual locations, with emission factors derived from contractual instruments

## NOTES

### Scope 3

- 2021 data is verified to the limited assurance level.
- Purchased goods and services & Capital goods – Emissions calculated based on spend using emission factors determined using average data methodology and DEFRA 2011 Table 13 emission factors adjusted for inflation.
- Fuel-and-energy-related activities – Fuel-related emissions calculated using UK Government GHG Conversion Factors for Company Reporting (2021). Emissions associated with production of electricity, heat and steam calculated using IEA Emission Factors 2021 Edition and include CO<sub>2</sub> emissions only.
- Upstream transportation & distribution – Includes emissions calculated using GHG Protocol emission factors and data reported directly by logistics suppliers. Transportation and distribution of Pfizer's COVID vaccine, shipped predominantly by air using cold chain technologies, contributed to approximately 75% increase in upstream logistics emissions in 2021. Additionally, the urgent need for certain Pfizer products to treat COVID patients and the impacts of the 2021 Suez Canal blockage on ocean freight prompted a shift from ocean transportation to air, further increasing logistics emissions.
- Waste generated in operations – Emissions calculated using UK Government GHG Conversion Factors for Company Reporting (2021).
- Business travel – Emissions calculated by Pfizer's travel partner, Advito, using a proprietary methodology certified under ISO 14064-1:2018 & 2019.
- Employee commuting – Emissions estimated using US EPA Climate Leaders GHG 2022, DEFRA, and IEA emission factors. Includes estimated emissions for colleagues working remotely.
- Upstream leased assets – Emissions estimated using the GHG Protocol Quantis Scope 3 Evaluator.
- Downstream transportation and distribution – Pfizer's methodology for estimating emissions changed in 2020. Emissions provided for the US only, calculated using Emission Factors from Cross-Sector Tools – GHG Protocol – March 2017.
- Investments – Emissions data provided by Pfizer's joint venture operations.

### Water

Pfizer strives to reduce freshwater use from its internal operations. Our Water Stewardship position statement describes our efforts to be good stewards of water with a particular focus on water stressed areas. To learn more about our efforts, see our [position statement](#). In 2021, the decrease in water withdrawal including non-contact cooling water was due primarily to the reduction in non-contact cooling water use at our Kalamazoo, Michigan manufacturing plant as the site shifted its focus to vaccine production, running 14% fewer fermentation lots in 2021 when compared to 2020. In addition, sites around the world have contributed to reductions in water withdrawal by implementing water conservation projects.

### Waste

Pfizer strives to reduce waste from its operation through applying a hierarchy of control of handling waste: reduce, reuse, recycle, disposal. Each site has established targets to improve the circularity of their waste and we benchmark our performance against others in our industry. In 2021, the decrease in hazardous waste generation was due to shifted focus on vaccine production with 14% reduction in fermentation lots. The increase in non-hazardous waste generation was due to vaccine production.

### Health & Safety

Pfizer's global total injury & illness rate and total lost time injury rate is based on OSHA recording criteria. In 2021, Pfizer's total injury & illness and lost time injury & illness rates were lower than pre-COVID-19 rates.

Increase in collisions per million km (CPMK) driven rate in 2021 was due to increase in commercial activities. The 2020 CPMK rate was impacted by reduction in commercial activities due to COVID-19.